Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cephradine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.98 |
| ▸ | MEN1 | O00255 | 4/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.98 |
| ▸ | BLM | P54132 | 2/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | PGR | P06401 | 1/20 | 0.98 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.98 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.98 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.67 |
| ▸ | SLC15A2 | Q16348 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cephradine SCHEMBL28758599 | 1.00 | MAPT (0.98) | MAPTHSD17B10KDM4EKMT2ACYP3A4 | |
| Cephradine SCHEMBL27547040 | 1.00 | MAPT (0.98) | MAPTHSD17B10KDM4EKMT2ACYP3A4 | |
| Cephradine SCHEMBL956675 | 1.00 | MAPT (0.98) | MAPTHSD17B10KDM4EKMT2ACYP3A4 | |
| Cephradine SCHEMBL16072830 | 0.99 | MAPT (1.00) | MAPTHSD17B10KDM4EKMT2ACYP3A4 | |
| Cephradine SCHEMBL20969062 | 0.99 | MAPT (1.00) | MAPTHSD17B10KDM4EKMT2ACYP3A4 | |
| Cephradine SCHEMBL11236414 | 0.99 | MAPT (1.00) | MAPTHSD17B10KDM4EKMT2ACYP3A4 | |
| Cephradine SCHEMBL11236409 | 0.99 | MAPT (1.00) | MAPTHSD17B10KDM4EKMT2ACYP3A4 | |
| Cephradine SCHEMBL13779346 | 0.99 | MAPT (1.00) | MAPTHSD17B10KDM4EKMT2ACYP3A4 | |
| Cephradine SCHEMBL3244 | 0.99 | MAPT (1.00) | MAPTHSD17B10KDM4EKMT2ACYP3A4 | |
| Cephradine SCHEMBL11209915 | 0.98 | MAPT (0.98) | MAPTHSD17B10KDM4EKMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119700983-A | Application of UBR5 in preparation of medicines for treating pigment dermatosis | 中南大学湘雅医院 | 2025-03-28 | — | — | CN | disclosed |
| CN-117024030-A | Multilayer slow-release additive for negative-temperature rush-repair concrete, preparation and use methods thereof | 中路交科科技股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-116466000-A | Method for rapidly determining 176 PPCPs content in source water | 福建省产品质量检验研究院(福建省缺陷产品召回技术中心) | 2023-07-21 | — | — | CN | disclosed |
| CN-110693888-B | Application of cefradine as bovine enterovirus inhibitor | 山东省农业科学院奶牛研究中心 | 2022-12-06 | — | — | CN | disclosed |
| WO-2021094458-A1 | NOVEL BROAD RANGE BETA-LACTAMASES | Centrient Pharmaceuticals Netherlands B.V. (NL) | 2021-05-20 | — | — | WO | disclosed |
| CN-112189804-A | Preparation method of fresh, tender, tasty and crispy chicken cutlet | 南京天策金粮餐饮管理有限公司 | 2021-01-08 | — | — | CN | disclosed |
| CN-110693888-A | Application of cefradine as bovine enterovirus inhibitor | 山东省农业科学院奶牛研究中心 | 2020-01-17 | — | — | CN | disclosed |
| US-20160361356-A1 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ENHANCING SURVIVABILITY OF CELLS, TISSUES, ORGANS, AND ORGANISMS | FRED HUTCHINSON CANCER RESEARCH CENTER | 2016-12-15 | — | — | US | disclosed |
| EP-2949212-A1 | USE OF OXYGEN ANTAGONISTS FOR EX VIVO PRESERVATION OF TISSUES OR ORGANS | Fred Hutchinson Cancer Research Center (US) | 2015-12-02 | — | — | EP | disclosed |
| US-20150164064-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | FRED HUTCHINSON CANCER RESEARCH CENTER | 2015-06-18 | — | — | US | disclosed |
| EP-1689228-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS | Fred Hutchinson Cancer Research Center (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1684579-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | Fred Hutchinson Cancer Research Center (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1684580-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN TISSUES AND ORGANS | Fred Hutchinson Cancer Research Center (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050170019-A1 | Methods, compositions and devices for inducing stasis in cells | FRED HUTCHINSON CANCER RESEARCH CENTER | 2005-08-04 | — | — | US | disclosed |
| CN-1637002-A | Cephalosporin ester compound resisting beta-lactamase and its salt | ZHEJIANG YONGNING PHARMACEUTIC (CN) | 2005-07-13 | — | — | CN | disclosed |
| US-20050147692-A1 | Methods, compositions and devices for inducing stasis in tissues and organs | FRED HUTCHINSON CANCER RESEARCH CENTER | 2005-07-07 | — | — | US | disclosed |
| US-20050136125-A1 | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-23 | — | — | US | disclosed |
| WO-2005041656-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN TISSUES AND ORGANS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005041655-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005039291-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361356-A1 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ENHANCING SURVIVABILITY OF CELLS, TISSUES, ORGANS, AND ORGANISMS | BCL2, BAX, HSF1 | MAPT 3662/4885HSD17B10 3687/4885KDM4E 3961/4885 |
| US-20050147692-A1 | Methods, compositions and devices for inducing stasis in tissues and organs | HIF1A, HIF1AN, PYGL | MAPT 4850/4885HSD17B10 3276/4885KDM4E 2861/4885 |
| US-20050136125-A1 | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | HSF1, HSP90AB1, HSP90AA1 | MAPT 2837/4885HSD17B10 2858/4885KDM4E 4710/4885 |
| US-20050170019-A1 | Methods, compositions and devices for inducing stasis in cells | PLAT, TBXA2R, THPO | MAPT 4786/4885HSD17B10 4427/4885KDM4E 2567/4885 |
| US-20150164064-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | HSF1, HSP90AB1, HSP90AA1 | MAPT 2837/4885HSD17B10 2858/4885KDM4E 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.